Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of S-337395 in high-risk nonhospitalized adults with RSV infection
jRCT2031250549Phase 2Recruiting
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Jan 2026
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing S-337395 arm with Placebo arm (2 arms). Primary endpoint: Change from baseline in RSV RNA load. Started Jan 2026; status: recruiting.
02
Drugs
S-337395
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on jRCT2031250549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250549.